Raman Bekarevich

Dr. Raman Bekarevich

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Journal of Power Sources
Verified
Journal Article
Closed access
RBRajendra Hongahally Basappa
Rajendra Hongahally Basappa
TITomoko Ito
Tomoko Ito
TMTakao Morimura
Takao Morimura
RBRaman Bekarevich
Raman Bekarevich
KMKazutaka Mitsuishi
Kazutaka Mitsuishi
Hirotoshi YamadaHirotoshi Yamada
Hirotoshi Yamada

15 August 2023 in Advanced Energy Materials
Verified
Journal Article
Open access
YPYuriy Pihosh
Yuriy Pihosh
VNVikas Nandal
Vikas Nandal
THTomohiro Higashi
Tomohiro Higashi
RSRyota Shoji
Ryota Shoji
RBRaman Bekarevich
Raman Bekarevich
KDKazunari Domen
Kazunari Domen
Designing photoanode semiconducting materials with visible‐light absorption and minimal charge‐carrier recombination for achieving efficient solar‐to‐hydrogen (STH) conversion is challenging. Here, hybrid Ta3N5 nanorods and thin films are developed on transparent GaN/Al2O3 substrates. A Ta3N5 photoanode with a loaded cocatalyst achieves the best current density, i.e. 10.8 mA cm−2, at 1.23 V versus the reversible hydrogen electrode under simulated AM 1.5G solar illumination. In a tandem configuration with dual‐CuInSe2 photovoltaic cells, this semi‐transparent photoanode achieves a reproducible STH energy conversion efficiency of ≈12% (the highest among photocatalytic materials), and remains at more than 10% for 6.7 h of tandem device operation. Detailed transient absorption spectroscopy and theoretical analysis indicates that this high performance originates from efficient light absorption and hole utilization inside the Ta3N5 material. The results show the feasibility of suppressing dominant optical and charge‐carrier‐ recombination losses by using nanostructured visible‐light‐absorbing materials for practical STH conversion.

7 April 2023 in ACS Energy Letters
Verified
Journal Article
Closed access
YPYuriy Pihosh
Yuriy Pihosh
VNVikas Nandal
Vikas Nandal
RSRyota Shoji
Ryota Shoji
RBRaman Bekarevich
Raman Bekarevich
THTomohiro Higashi
Tomohiro Higashi
KDKazunari Domen
Kazunari Domen

1 November 2017 in Journal of Power Sources
Verified
Journal Article
Closed access
Hirotoshi YamadaHirotoshi Yamada
Hirotoshi Yamada
TITomoko Ito
Tomoko Ito
RBRajendra Hongahally Basappa
Rajendra Hongahally Basappa
RBRaman Bekarevich
Raman Bekarevich
KMKazutaka Mitsuishi
Kazutaka Mitsuishi

31 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Alexander ZaboronokAlexander Zaboronok
Alexander Zaboronok
PKPolina Khaptakhanova
Polina Khaptakhanova
SUSergey Uspenskii
Sergey Uspenskii
RBRaman Bekarevich
Raman Bekarevich
LMLudmila Mechetina
Ludmila Mechetina
AMAkira Matsumura
Akira Matsumura
Sufficient boron-10 isotope (10B) accumulation by tumor cells is one of the main requirements for successful boron neutron capture therapy (BNCT). The inability of the clinically registered 10B-containing borophenylalanine (BPA) to maintain a high boron tumor concentration during neutron irradiation after a single injection has been partially solved by its continuous infusion; however, its lack of persistence has driven the development of new compounds that overcome the imperfections of BPA. We propose using elemental boron nanoparticles (eBNPs) synthesized by cascade ultrasonic dispersion and destruction of elemental boron microparticles and stabilized with hydroxyethylcellulose (HEC) as a core component of a novel boron drug for BNCT. These HEC particles are stable in aqueous media and show no apparent influence on U251, U87, and T98G human glioma cell proliferation without neutron beam irradiation. In BNCT experiments, cells incubated with eBNPs or BPA at an equivalent concentration of 40 µg 10B/mL for 24 h or control cells without boron were irradiated at an accelerator-based neutron source with a total fluence of thermal and epithermal neutrons of 2.685, 5.370, or 8.055 × 1012/cm2. The eBNPs significantly reduced colony-forming capacity in all studied cells during BNCT compared to BPA, verified by cell-survival curves fit to the linear-quadratic model and calculated radiobiological parameters, though the effect of both compounds differed depending on the cell line. The results of our study warrant further tumor targeting-oriented modifications of synthesized nanoparticles and subsequent in vivo BNCT experiments.

21 May 2020 in ACS Applied Energy Materials
Verified
Journal Article
Closed access
RBRaman Bekarevich
Raman Bekarevich
YPYuriy Pihosh
Yuriy Pihosh
YTYoshinori Tanaka
Yoshinori Tanaka
KNKei Nishikawa
Kei Nishikawa
YMYoshitaka Matsushita
Yoshitaka Matsushita
KTKazunori Takada
Kazunori Takada